🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 45781M101 (prev. 88338T104 )
- Market Cap
- Large Cap
- IPO
- 10/5/2004 · $16.00/share
- Previous Symbol
- THRX (changed 1/8/2016)
- Previous Name
- Theravance, Inc.
Business: Innoviva, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK.
Notes: 06/02/14 -- Theravance, Inc. (NASDAQ: THRX) (Theravance) and Theravance Biopharma, Inc. (NASDAQ: TBPH) (Theravance Biopharma) today announced the completion of the separation of Theravance Biopharma, Inc., the research and development-based biopharmaceutical business, from Theravance, Inc. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders.
Theravance, Inc., A Royalty Management Company, is focused on maximizing the potential value of the respiratory assets partnered with GlaxoSmithKline plc and providing capital returns to stockholders, while Theravance Biopharma is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (CNS)/pain, respiratory disease and gastrointestinal motility dysfunction.
Company Contact
- CEO
- Pavel Raifeld
- CFO
- Stephen Basso
- Headquarters
- 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010
- Phone
- 650-238-9600 · Toll-Free 877-202-1097
- Investor Relations
- Argot Partners · 212-600-1902 · innoviva@argotpartners.com